These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35966026)

  • 1. Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO-Insights From a Mechanistic PK/PD Model of Bone Turnover.
    Martínez-Reina J; Calvo-Gallego JL; Martin M; Pivonka P
    Front Bioeng Biotechnol; 2022; 10():886579. PubMed ID: 35966026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    J Mech Behav Biomed Mater; 2021 Jan; 113():104140. PubMed ID: 33080564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    Front Bioeng Biotechnol; 2021; 9():635056. PubMed ID: 34150724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization.
    Martínez-Reina J; Pivonka P
    Bone; 2019 Aug; 125():87-95. PubMed ID: 31055117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
    Hong N; Shin S; Lee S; Kim KJ; Rhee Y
    Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
    Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
    Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab Discontinuation.
    Sølling AS; Tsourdi E; Harsløf T; Langdahl BL
    Curr Osteoporos Rep; 2023 Feb; 21(1):95-103. PubMed ID: 36564572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
    Burckhardt P; Faouzi M; Buclin T; Lamy O;
    J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
    Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
    J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
    Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.
    Sánchez A; Brun LR; Salerni H; Costanzo PR; González D; Bagur A; Oliveri B; Zanchetta MB; Farías V; Maffei L; Premrou V; Mansur JL; Larroudé MS; Sarli MA; Rey P; Ulla MR; Pavlove MM; Karlsbrum S; Brance ML
    J Osteoporos; 2016; 2016():8738959. PubMed ID: 27579211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
    Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
    J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
    Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
    J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
    Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
    J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.
    Ominsky MS; Libanati C; Niu QT; Boyce RW; Kostenuik PJ; Wagman RB; Baron R; Dempster DW
    J Bone Miner Res; 2015 Jul; 30(7):1280-9. PubMed ID: 25684625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.